Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRVS 
Corvus Pharmaceuticals Inc (CRVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: CRVS (3-star) is a STRONG-BUY. BUY since 46 days. Simulated Profits (45.15%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15
1 Year Target Price $15
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1208.02% | Avg. Invested days 32 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 570.03M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 6 | Beta 0.56 | 52 Weeks Range 2.54 - 10.00 | Updated Date 10/18/2025 |
52 Weeks Range 2.54 - 10.00 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.85% | Return on Equity (TTM) -68.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 451254834 | Price to Sales(TTM) - |
Enterprise Value 451254834 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.36 | Shares Outstanding 74514039 | Shares Floating 57356436 |
Shares Outstanding 74514039 | Shares Floating 57356436 | ||
Percent Insiders 3.96 | Percent Institutions 56.33 |
Upturn AI SWOT
Corvus Pharmaceuticals Inc
Company Overview
History and Background
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies that target the tumor microenvironment to activate the immune system to attack cancer. It was founded in 2011.
Core Business Areas
- Product Development: Focuses on the development of novel cancer therapies, primarily targeting the tumor microenvironment and the immune system.
Leadership and Structure
The leadership team includes Richard A. Miller, Ph.D., as CEO, and the company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Soquelitin (CPI-818): Soquelitin is an investigational ITK inhibitor being developed for T cell lymphomas. It has not yet received market approval. Competitors include companies developing therapies for T-cell lymphoma, such as Kyowa Kirin (Poteligeo).
- CPI-006: CPI-006 is an anti-CD73 antibody designed to block the production of adenosine in the tumor microenvironment. Clinical trials are ongoing. Competitors are numerous and include companies developing similar CD73 inhibitors or other immunotherapies like AstraZeneca (Imfinzi) and Bristol Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Immunotherapy for cancer is a rapidly growing area.
Positioning
Corvus is positioned as a company focused on novel immunotherapy approaches targeting the tumor microenvironment. Its competitive advantage relies on the unique mechanisms of action of its drug candidates.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is substantial, projected to be in the tens of billions of dollars annually. Corvus aims to capture a portion of this market with its novel therapies.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Strong scientific team
- Potential for first-in-class therapies
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Dependence on partnered or future funding
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of clinical trials to new indications
- Positive clinical trial results leading to regulatory approval
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AZN
- BMY
- GILD
Competitive Landscape
Corvus faces intense competition from larger, well-established pharmaceutical companies. Its success depends on differentiating its therapies and demonstrating clinical superiority.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, as the company is primarily focused on drug development and has not yet generated significant product revenue.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary widely and are highly speculative.
Recent Initiatives: Recent initiatives include advancing clinical trials for Soquelitin and CPI-006, and seeking potential partnerships.
Summary
Corvus Pharmaceuticals is a high-risk, high-reward clinical-stage company with a focus on innovative cancer immunotherapy. While its novel approach and scientific team are strengths, its reliance on clinical trial success and limited financial resources present challenges. Success hinges on advancing its pipeline and securing strategic partnerships, especially because of intense competition from larger pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Company presentations
- Clinicaltrials.gov
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corvus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2016-03-23 | Co-Founder, President, CEO & Chairman of the Board Dr. Richard A. Miller M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.corvuspharma.com |
Full time employees 31 | Website https://www.corvuspharma.com | ||
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.